BCL2 and Miyoshi myopathy: While the results of MM treatment with Venetoclax underline the potential of using BH3-mimetics in MM, they also suggest that Venetoclax may only be effective in a subset of patients, namely those who have relatively high BCL-2 and relatively low MCL-1.